Last reviewed · How we verify

sinemet plus — Competitive Intelligence Brief

sinemet plus (sinemet plus) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine replacement therapy with COMT inhibitor. Area: Neurology.

marketed Dopamine replacement therapy with COMT inhibitor Dopamine pathway; COMT enzyme Neurology Small molecule Live · refreshed every 30 min

Target snapshot

sinemet plus (sinemet plus) — Hospital de Granollers. Sinemet Plus combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) and entacapone (a COMT inhibitor) to increase dopamine availability in the brain for Parkinson's disease treatment.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
sinemet plus TARGET sinemet plus Hospital de Granollers marketed Dopamine replacement therapy with COMT inhibitor Dopamine pathway; COMT enzyme
Levodopa/carbidopa/entacapone Levodopa/carbidopa/entacapone Novartis marketed Dopamine precursor with decarboxylase inhibitor and COMT inhibitor Dopamine pathway; COMT enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine replacement therapy with COMT inhibitor class)

  1. Hospital de Granollers · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sinemet plus — Competitive Intelligence Brief. https://druglandscape.com/ci/sinemet-plus. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: